A Phase 1b, Randomised, Controlled, Observer-blinded Trial to Assess Safety, Tolerability and Pharmacodynamic Effects of LEO 134310 Cutaneous Solution in Descaled Skin of Adults With Chronic Plaque Psoriasis
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2019
At a glance
- Drugs LP 0155 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors LEO Pharma
- 05 Feb 2019 Status changed from recruiting to completed.
- 25 Oct 2018 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019.
- 25 Oct 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2019.